59 related articles for article (PubMed ID: 2941893)
1. [Marvelon--when the adverse effects become a marketing argument].
Hansson V
Tidsskr Nor Laegeforen; 1986 Apr; 106(11):966-8. PubMed ID: 2941893
[No Abstract] [Full Text] [Related]
2. [Marvelon--when adverse effects become marketing arguments].
Fjaerestad I
Tidsskr Nor Laegeforen; 1986 Aug; 106(23):1865-6. PubMed ID: 2945284
[No Abstract] [Full Text] [Related]
3. [Marvelon--when adverse effects became marketing arguments].
Fjoerestad I
Tidsskr Nor Laegeforen; 1986 Aug; 106(22):1735-8. PubMed ID: 2946094
[No Abstract] [Full Text] [Related]
4. Comparative effects of combined oral contraceptives containing desogestrel or levonorgestrel on serum lipids, lipoproteins and sex hormone binding globulin in healthy women.
Sirimongkolkasem R; Rojanasakul A; Phiromsawat S; Chailurkit L
J Med Assoc Thai; 1988 Jul; 71 Suppl 2():68-73. PubMed ID: 2972791
[TBL] [Abstract][Full Text] [Related]
5. Desogestrel: using a selective progestogen in a combined oral contraceptive.
op ten Berg M
Adv Contracept; 1991; 7(2-3):241-50. PubMed ID: 1835255
[TBL] [Abstract][Full Text] [Related]
6. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
[TBL] [Abstract][Full Text] [Related]
7. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
Odlind V; Milsom I; Persson I; Victor A
Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
[TBL] [Abstract][Full Text] [Related]
8. [Laboratory and clinical study with a new progestagen combined with ethinyl estradiol used in contraception].
Galán G; Gayán P; Tisné L
Rev Chil Obstet Ginecol; 1985; 50(4):317-24. PubMed ID: 2953049
[No Abstract] [Full Text] [Related]
9. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
Coenen CM; Thomas CM; Borm GF; Rolland R
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
[TBL] [Abstract][Full Text] [Related]
10. Third generation oral contraceptive pills.
MacRae K; Kay C
BMJ; 1995 Oct; 311(7013):1112. PubMed ID: 7580698
[No Abstract] [Full Text] [Related]
11. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
Rákóczi I; Gerö G; Demeter J; Gáti I
Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
[TBL] [Abstract][Full Text] [Related]
12. [Criticizing the criticism].
Heinzl S
Med Monatsschr Pharm; 1990 Aug; 13(8):233. PubMed ID: 2398838
[No Abstract] [Full Text] [Related]
13. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
Meurer LN; Slawson JG
J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
[No Abstract] [Full Text] [Related]
14. [Efficacy of oral contraceptives on acne. Apropos of a comparative study of Varnoline vs Diane in 69 women with acne].
Levrier M; Degrelle H; Bestaux Y; Bourry-Moreno M; Brun JP; Sailly F
Rev Fr Gynecol Obstet; 1988; 83(7-9):573-6. PubMed ID: 2973646
[TBL] [Abstract][Full Text] [Related]
15. Third generation oral contraceptives containing desogestrel and gestodene and the risk of thrombosis.
Griffin JP
Adverse Drug React Toxicol Rev; 1996 Mar; 15(1):5-7. PubMed ID: 8920631
[No Abstract] [Full Text] [Related]
16. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
[No Abstract] [Full Text] [Related]
17. Desogestrel-containing oral contraceptives and blood pressure.
Dieben TO; van Beek A
Arzneimittelforschung; 1986 Nov; 36(11):1678-80. PubMed ID: 2949757
[TBL] [Abstract][Full Text] [Related]
18. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
Winkler UH; Sudik R
Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
Weijers MJ
Clin Ther; 1982; 4(5):359-66. PubMed ID: 6461412
[TBL] [Abstract][Full Text] [Related]
20. Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.
Stanczyk FZ; Grimes DA
Contraception; 2008 Sep; 78(3):201-3. PubMed ID: 18692609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
